Plain-English translation of NCT05761028 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing , a new injectable medication, to see if it can help people with moderate to severe asthma breathe better and have fewer asthma attacks. The trial will compare this medication (given in two different doses) against a placebo (a dummy injection with no active drug) over one year. About 600 people will participate across multiple hospitals and clinics.
Many people with moderate to severe asthma still struggle to control their symptoms even when taking standard asthma medications. This medication is designed to work in a new way to reduce asthma attacks and improve how well people can breathe.
You likely qualify if…
You likely don't qualify if…
You will start with a screening visit over up to 4 weeks to confirm you qualify. Then you'll receive an injection under your skin once every two weeks for one year (26 total injections) — either the new medication at a higher dose, the medication at a lower dose, or a placebo. After one year, you'll have a final 4-week follow-up period to make sure everything is safe. Throughout the study, researchers will track how well you're breathing, how many asthma attacks you have, and any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Enrollment target
~600 participants
Started
April 2023
Primary completion
May 2032
Age range
12 Years – 75 Years
Last updated on clinicaltrials.gov in December 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wang Wenjuan
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.